title: Infliximab in refractory uveitis due to Behçet's disease.
abstract: OBJECTIVE
  To report 4 cases of refractory panuveitis due to Behçet's disease treated with a novel therapy: infliximab.
  
  
  METHODS
  Retrospective study of 3 women and 1 man of Causasian origin with Behçet's disease complicated with panuveitis. Their uveitis was relapsing from 48 to 96 months and was resistant to the combination of colchicine (n = 4), high-dose prednisone (n = 4), pentoxyphilline (n = 2) and various immunossuppressors and/or immunomodulators given successively: intravenous cyclophosphamide (n = 4), azathioprine (n = 3), interferon alpha (n = 3), cyclosporine A (n = 2), oral cyclophosphamide (n = 1), mycophenolate mofetil (n = 1), methotrexate (n = 1), high-dose immunoglobulin (n = 1). Combination with respectively 1, 3, 4 and 5 immunossuppressors and/or immunomodulators failed before institution of infliximab. After informed consent was obtained, infliximab was administered as a single infusion of 5 mg/kg (maximum dose: 400 mg) at day 1, at week 2, 6 and then every 8 weeks.
  
  
  RESULTS
  With a follow-up ranging from 7 to 22 months, infliximab was efficient in all cases. The mean prednisone dose decreased from 45 mg to 13 mg daily. Total recovery of visual acuity was observed in half of the cases. Infliximab was well tolerated without fever, severe sepsis or autoimmune manifestation.
  
  
  CONCLUSIONS
  Infliximab may be efficient in refractory uveitis due to Behçet's disease. The optimal dose, rhythm and duration of infliximab infusions need to be standardized.
authors.affiliation: Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Wechsler
authors.forename: R
authors.initials: R
authors.lastname: Sablé-Fourtassou
authors.forename: B
authors.initials: B
authors.lastname: Bodaghi
authors.forename: D L T
authors.initials: DL
authors.lastname: Huong
authors.forename: N
authors.initials: N
authors.lastname: Cassoux
authors.forename: I
authors.initials: I
authors.lastname: Badelon
authors.forename: O
authors.initials: O
authors.lastname: Fain
authors.forename: P
authors.initials: P
authors.lastname: LeHoang
authors.forename: J-C
authors.initials: JC
authors.lastname: Piette
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy*; D002648:Child; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D015864:Panuveitis / Q000188:drug therapy* / Q000209:etiology; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab